Acrivon Therapeutics (ACRV) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Retension Pharmaceuticals is the larger company by market cap ($89.2 million vs $81.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ACRV | RTSN |
|---|---|---|
| Share price | $1.90 | $11.32 |
| Market cap | $81.42M | $89.22M |
| 1-day change | -0.52% | +7.50% |
| YTD return | -21.16% | — |
| 1-year return | +7.34% | — |
| EPS (TTM) | $-1.88 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $11.79 |
| 52-week low | $1.27 | $9.66 |
| Distance from 52-week high | -46.63% | -3.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +505.26% | — |
| Average volume | 353.72K | 789.20K |
| Shares outstanding | 42.85M | 7.88M |
| Employees | 74 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ACRV vs RTSN FAQ
Which is bigger, Acrivon Therapeutics or Retension Pharmaceuticals?
Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $89.22M compared with $81.42M for Acrivon Therapeutics (ACRV).
Are Acrivon Therapeutics and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.